INCB161734 + mFOLFIRINOX

**INCB161734 + mFOLFIRINOX** is an experimental combination regimen for the treatment of cancer, particularly pancreatic cancer. **INCB161734** is a novel investigational drug—its class, target, and developer are not defined by currently available data, but it is presumably an inhibitor or targeted agent under clinical investigation (based on its code name and trial co-usage with chemotherapy). **mFOLFIRINOX (modified FOLFIRINOX)** is a combination chemotherapy regimen consisting of oxaliplatin, leucovorin (folinic acid), irinotecan, and 5-fluorouracil (5-FU), administered intravenously. The regimen is used (with adjusted, more tolerable dosing) as a first-line or adjuvant therapy for resectable, unresectable, or metastatic pancreatic adenocarcinoma. mFOLFIRINOX inhibits cell division and induces cancer cell death through DNA cross-linking, inhibition of topoisomerase I, and antimetabolite effects of 5-FU. The combined regimen likely aims to leverage both direct cytotoxic and targeted mechanisms for enhanced antitumor efficacy in gastrointestinal malignancies.